Management of Herpes Simplex Virus Infection in Pregnant Women
Primary Recommendation for Herpes Simplex Virus (HSV) Infection
- The American College of Obstetricians and Gynecologists recommends treating pregnant women with acute first-episode genital herpes with valacyclovir 1 g orally twice daily for 7-10 days, and for women with recurrent genital herpes, initiate suppressive therapy with valacyclovir 1000 mg orally twice daily starting at 36 weeks gestation and continuing until delivery 1, 2
- For life-threatening maternal HSV infection, the Centers for Disease Control and Prevention recommends using intravenous acyclovir 5 mg/kg every 8 hours 1, 3
Treatment Algorithm for HSV in Pregnancy
- The recommended treatment for first-episode genital herpes is valacyclovir 1 g orally twice daily for 7-10 days, with an alternative option of acyclovir 400 mg orally three times daily for 7-10 days 1
- For recurrent genital herpes, suppressive prophylaxis should begin at 36 weeks gestation with valacyclovir 1000 mg orally twice daily or acyclovir 400 mg orally three times daily 2
Critical Context: Neonatal Transmission Risk
- The risk of neonatal transmission is significantly higher for primary HSV infection acquired near delivery, with a transmission risk of 30-50%, compared to recurrent HSV at term, which has a transmission risk of ≤3% 1, 2
Management at Delivery
- The American College of Obstetricians and Gynecologists recommends cesarean delivery for women with visible genital lesions or prodromal symptoms at labor onset, as it reduces transmission risk by approximately 85% 2
Special Populations
- For HIV-infected pregnant women, the same safety profile for valacyclovir applies, and some experts recommend prophylaxis for those with frequent, severe recurrences 1
- Immunocompromised patients may require higher doses of acyclovir, and if lesions persist during treatment, acyclovir resistance should be suspected 1